Company intelligence / Profile preview
Trigen Holdings
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Trigen Holdings was a London-based biopharmaceutical company focused on the development of novel antithrombotic therapies for cardiovascular diseases. The company's research centered on the coagulation cascade and platelet aggregation, aiming to create safer and more effective anticoagulants. Its lead clinical candidate, TGN 255, was a parenteral direct thrombin inhibitor that reached Phase 2 clinical trials for the prevention of deep vein thrombosis. Additionally, Trigen developed a pipeline of Factor Xa inhibitors and Glycoprotein VI antagonists. In 2006, the company was acquired by MediGene AG in an all-share transaction to expand MediGene's portfolio into the cardiovascular space.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small moleculePeptidesAntibody
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Trigen Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trigen Holdings.